COMPARISON OF GLYCEMIC CONTROL ACTIVITY OF SGLT2 INHIBITORS AND SULPHONYLUREAS IN PATIENTS OF IHD
DOI:
https://doi.org/10.71000/543kt076Abstract
The prevalence of Diabetes mellitus (DM) has escalated in the previous decades and is among the major risk factors for developing cardiovascular diseases.1,2 Multiple factors play role in progression of DM towards micro and macrovascular complications. However, poor glycemic control is a main contributor towards the adverse disease outcomes and has been of prime importance in decision making regarding antidiabetic medications.
Methodology: It was a longitudinal cross-sectional study conducted in CMH Jhelum using non-probability convenient sampling technique. Patients having DM and IHD for atleast 1year and with inadequate glycemic control with metformin were selected and analyzed according to demographic details, duration of DM & IHD, therapy group (SGLT2 inhibitors/SU), dosage regimen, incidence of hypoglycemia, comorbidities, history of coronary intervention, baseline and 3-monthly fasting and post-prandial glucose, HbA1c and metabolic profile. Chi square test was applied to find significant difference between both groups and p-value of <0.05 was considered significant.
Results: Among total of 70 patients, 35 patients were divided into each group (Sulphonylureas vs SGLT inhibitors). Both groups had comparable baseline profiles which included gender [males: 17(48.57%) vs 16(45.71%), females: 18(51.43%) vs 19(54.29%) ], duration of diabetes (8.37 ± 2.59 vs 8.86 ± 2.43 years, p=0.417) and IHD (7.63 ± 2.68 vs. 7.46 ± 2.52 years, p=0.854), history of coronary intervention (48.57% vs. 54.29%, p=0.632), hypoglycemia (34.29% vs. 48.57%, p=0.225), hypertension (51.43% vs. 34.29%, p=0.147), and dyslipidemia (48.57% vs. 45.71%, p=0.811). Comparison of both groups in glycemic control activity showed almost comparable reduction in fasting blood glucose in both groups ((132.20±19.79 vs 138.69±18.56, p-value=0.143) at 3-monthly follow-up from baseline (159.80±19.52 vs 161.74±18.57, p-value=0.778). However, there was significant difference in reduction in post-prandial glucose (169.40±20.09 vs 159.43±21.45, p-value 0.052) from baseline (198.31±19.71 vs 196.91±21.52, p-value=-0.733) and HbA1c (7.49±0.63 vs 7.05±0.64, p-value=0.006) from baseline (8.26±0.61 vs 8.09±0.59, p-value=0.212) at 3-monthly follow-up.
Conclusion: SGLT2 inhibitors have greater impact in reducing HbA1c and post-prandial blood glucose as compared to SU but further research is needed to elaborate this comparison.
The prevalence of Diabetes mellitus (DM) has escalated in the previous decades and is among the major risk factors for developing cardiovascular diseases.1,2 Multiple factors play role in progression of DM towards micro and macrovascular complications. However, poor glycemic control is a main contributor towards the adverse disease outcomes and has been of prime importance in decision making regarding antidiabetic medications.
Methodology: It was a longitudinal cross-sectional study conducted in CMH Jhelum using non-probability convenient sampling technique. Patients having DM and IHD for atleast 1year and with inadequate glycemic control with metformin were selected and analyzed according to demographic details, duration of DM & IHD, therapy group (SGLT2 inhibitors/SU), dosage regimen, incidence of hypoglycemia, comorbidities, history of coronary intervention, baseline and 3-monthly fasting and post-prandial glucose, HbA1c and metabolic profile. Chi square test was applied to find significant difference between both groups and p-value of <0.05 was considered significant.
Results: Among total of 70 patients, 35 patients were divided into each group (Sulphonylureas vs SGLT inhibitors). Both groups had comparable baseline profiles which included gender [males: 17(48.57%) vs 16(45.71%), females: 18(51.43%) vs 19(54.29%) ], duration of diabetes (8.37 ± 2.59 vs 8.86 ± 2.43 years, p=0.417) and IHD (7.63 ± 2.68 vs. 7.46 ± 2.52 years, p=0.854), history of coronary intervention (48.57% vs. 54.29%, p=0.632), hypoglycemia (34.29% vs. 48.57%, p=0.225), hypertension (51.43% vs. 34.29%, p=0.147), and dyslipidemia (48.57% vs. 45.71%, p=0.811). Comparison of both groups in glycemic control activity showed almost comparable reduction in fasting blood glucose in both groups ((132.20±19.79 vs 138.69±18.56, p-value=0.143) at 3-monthly follow-up from baseline (159.80±19.52 vs 161.74±18.57, p-value=0.778). However, there was significant difference in reduction in post-prandial glucose (169.40±20.09 vs 159.43±21.45, p-value 0.052) from baseline (198.31±19.71 vs 196.91±21.52, p-value=-0.733) and HbA1c (7.49±0.63 vs 7.05±0.64, p-value=0.006) from baseline (8.26±0.61 vs 8.09±0.59, p-value=0.212) at 3-monthly follow-up.
Conclusion: SGLT2 inhibitors have greater impact in reducing HbA1c and post-prandial blood glucose as compared to SU but further research is needed to elaborate this comparison.
References
Aroda VR, Eckel RH. Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment. Diabetes, Obesity and Metabolism. 2022 Dec;24(12):2297-308.
Bonaventura A, Carbone S, Dixon DL, Abbate A, Montecucco F. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT‐2 inhibitors and GLP‐1 receptor agonists. Journal of internal medicine. 2019 Jul;286(1):16-31.
Martinez M, Santamarina J, Pavesi A, Musso C, Umpierrez GE. Glycemic variability and cardiovascular disease in patients with type 2 diabetes. BMJ open diabetes research & care. 2021 Mar 24;9(1).Oikonomou E, Xenou M, Zakynthinos GE, Tsaplaris P, Lampsas S, Bletsa E, Gialamas I, Kalogeras K, Goliopoulou A, Gounaridi MI, Pesiridis T. Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease. Current Pharmaceutical Design. 2023 Jun 1;29(23):1844-62.
Haq FU, Siraj A, Ameer MA, Hamid T, Rahman M, Khan S, Khan S, Masud S. Comparative review of drugs used in diabetes mellitus—new and old. Journal of diabetes mellitus. 2021;11(04):115-31.
Wang W, Chen LY, Walker RF, Chow LS, Norby FL, Alonso A, Pankow JS, Lutsey PL. SGLT2 Inhibitors Are Associated With Reduced Cardiovascular Disease in Patients With Type 2 Diabetes: An Analysis of Real-World Data. InMayo Clinic Proceedings 2023 Jul 1 (Vol. 98, No. 7, pp. 985-996). Elsevier.
Oikonomou E, Xenou M, Zakynthinos GE, Tsaplaris P, Lampsas S, Bletsa E, Gialamas I, Kalogeras K, Goliopoulou A, Gounaridi MI, Pesiridis T. Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease. Current Pharmaceutical Design. 2023 Jun 1;29(23):1844-62.
Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Al-Aly Z. Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors vs sulfonylureas in patients with type 2 diabetes. JAMA internal medicine. 2021 Aug 1;181(8):1043-53.
E, Ahsan T, Ghaus S, Aijaz W. SGLT 2 Inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute (MIDEM). Pakistan Journal of Medical Sciences. 2021 Jan;37(1):87.
Lee SJ, Lee KH, Oh HG, Seo HJ, Jeong SJ, Kim CH. Effect of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase 4 inhibitors on cardiovascular function in patients with type 2 diabetes mellitus and coronary artery disease. Journal of Obesity & Metabolic Syndrome. 2019 Dec 30;28(4):254.
Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, Filippatos G, Coats AJ, Anker SD. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis. ESC heart failure. 2020 Dec;7(6):3298-309.
Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta‐analysis of cardiovascular outcome trials and intensive glucose control trials. Journal of the American Heart Association. 2019 Jun 18;8(12):e012356.
Hougen I, Whitlock RH, Komenda P, Rigatto C, Clemens KK, Tangri N. Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study. BMJ Open Diabetes Research and Care. 2021 Dec 1;9(2):e002352.
Li-Nong JI, Yun-Dai CH, Cardiovascular Subcommittee of Chinese International Exchange and Promotion Association for Medical and Healthcare. Consensus on glycemic management for patients with coronary heart disease and type 2 diabetes. Journal of Geriatric Cardiology: JGC. 2024 Jul 28;21(7):689.
McMurray JJ, Solomon SD, Docherty KF, Jhund PS. The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal. 2021 Apr 1;42(13):1199-202.
Zhu J, Zhou Y, Li Q, Wang G. Cost-effectiveness of newer antidiabetic drugs as second-line treatment for type 2 diabetes: a systematic review. Advances in Therapy. 2023 Oct;40(10):4216-35.
Wang H, Cordiner RL, Huang Y, Donnelly L, Hapca S, Collier A, McKnight J, Kennon B, Gibb F, McKeigue P, Wild SH. Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nationwide population-based comparative safety study. Diabetes Care. 2023 May 1;46(5):967-77.
Chen Z, Li G. Sodium-glucose co-transporter 2 inhibitors compared with sulfonylureas in patients with type 2 diabetes inadequately controlled on metformin: a meta-analysis of randomized controlled trials. Clinical drug investigation. 2019 Jun 1;39(6):521-31.
Wilkinson S, Williamson E, Pokrajac A, Fogarty D, Stirnadel‐Farrant H, Smeeth L, Douglas IJ, Tomlinson LA. Comparative effects of sulphonylureas, dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors added to metformin monotherapy: a propensity‐score matched cohort study in UK primary care. Diabetes, Obesity and Metabolism. 2020 May;22(5):847-56.
Cokro F, Sauriasari R, Tahapary DL, Setiawan H. Effects of SGLT2 Inhibitors Compared with Sulfonylurea on Glycaemic Control and Cardiovascular Risk Reduction in Asia: Meta-Analysis. Pharmaceutical Sciences Asia. 2024 Oct 1;51(4).
Durcan E, Ozkan S, Saygi HI, Dincer MT, Korkmaz OP, Sahin S, Karaca C, Sulu C, Bakir A, Ozkaya HM, Trabulus S. Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia. Journal of Diabetes. 2022 Apr;14(4):236-46.
Li N, Lv D, Zhu X, Wei P, Gui Y, Liu S, Zhou E, Zheng M, Zhou D, Zhang L. Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis. Frontiers in Medicine. 2021 Nov 1;8:728089.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Zaboor Ahmed, Waheed Ahmed, Farah Rao, Brigadier Abid Javaid Randhawa, Major Muhammad Usman Khan, Major Syed Haider Tirmizi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
